Seagen Inc. SGEN
We take great care to ensure that the data presented and summarized in this overview for Seagen Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SGEN
View all-
Pictet Asset Management Sa Geneva 73, V8802KShares$00.19% of portfolio
-
Berry Street Capital Management LLP London, X0206KShares$012.86% of portfolio
-
Tekla Capital Management LLC112KShares$00.86% of portfolio
-
Stansberry Asset Management, LLC New York, NY58.4KShares$02.24% of portfolio
-
Eaton Vance Management Boston, MA51.3KShares$00.01% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC23KShares$02.7% of portfolio
-
Mario Gabelli Gamco Investors, Inc. Et Al | Rye, Ny18.6KShares$00.05% of portfolio
-
Seeyond Paris, I014.3KShares$00.18% of portfolio
-
Terrapin Asset Management, LLC Miami, FL14KShares$03.38% of portfolio
-
Allstate Investment Management CO Northbrook, IL6.21KShares$00.02% of portfolio
Latest Institutional Activity in SGEN
Top Purchases
Top Sells
About SGEN
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Insider Transactions at SGEN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 14
2023
|
Baker Bros. Advisors LP Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
44,708,503
-100.0%
|
$10,238,247,187
$229.0 P/Share
|
|
Dec 14
2023
|
Baker Bros. Advisors LP Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
46,557
-100.0%
|
$10,661,553
$229.0 P/Share
|
|
Dec 14
2023
|
Vaughn B Himes Chief Technical Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
119,471
-100.0%
|
$27,358,859
$229.0 P/Share
|
|
Dec 14
2023
|
Vaughn B Himes Chief Technical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,874
-100.0%
|
$3,406,146
$229.0 P/Share
|
|
Dec 14
2023
|
Nancy A Simonian |
SELL
Sale (or disposition) back to the issuer
|
Direct |
62,753
-100.0%
|
$14,370,437
$229.0 P/Share
|
|
Dec 14
2023
|
Ted W Love |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,255
-100.0%
|
$974,395
$229.0 P/Share
|
|
Dec 14
2023
|
Todd E Simpson Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
93,292
-100.0%
|
$21,363,868
$229.0 P/Share
|
|
Dec 14
2023
|
Sandra M Swain |
SELL
Sale (or disposition) back to the issuer
|
Direct |
778
-100.0%
|
$178,162
$229.0 P/Share
|
|
Dec 14
2023
|
Daniel G Welch |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
10,725
-100.0%
|
$2,456,025
$229.0 P/Share
|
|
Dec 14
2023
|
Daniel G Welch |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,750
-100.0%
|
$1,087,750
$229.0 P/Share
|
|
Dec 14
2023
|
Jean I Liu Chief Legal Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
48,748
-100.0%
|
$11,163,292
$229.0 P/Share
|
|
Dec 14
2023
|
Alpna Seth |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,953
-100.0%
|
$2,966,237
$229.0 P/Share
|
|
Dec 14
2023
|
David R Epstein CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,407
-100.0%
|
$3,757,203
$229.0 P/Share
|
|
Dec 14
2023
|
David W Gryska |
SELL
Sale (or disposition) back to the issuer
|
Direct |
49,003
-100.0%
|
$11,221,687
$229.0 P/Share
|
|
Dec 14
2023
|
Roger D Dansey President, R&D & CMO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
38,338
-100.0%
|
$8,779,402
$229.0 P/Share
|
|
Dec 14
2023
|
John A Orwin |
SELL
Sale (or disposition) back to the issuer
|
Direct |
29,003
-100.0%
|
$6,641,687
$229.0 P/Share
|
|
Dec 14
2023
|
Charles R Romp EVP, Commercial U.S. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
33,796
-100.0%
|
$7,739,284
$229.0 P/Share
|
|
Nov 10
2023
|
David R Epstein CEO |
SELL
Open market or private sale
|
Direct |
10,620
-7.21%
|
$2,262,060
$213.01 P/Share
|
|
Nov 09
2023
|
Vaughn B Himes Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
8,785
-8.6%
|
$1,871,205
$213.6 P/Share
|
|
Sep 21
2023
|
Roger D Dansey President, R&D & CMO |
SELL
Open market or private sale
|
Direct |
71
-0.06%
|
$14,626
$206.5 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 142K shares |
|---|---|
| Other acquisition or disposition | 418K shares |
| Exercise of conversion of derivative security | 61.8K shares |
| Sale (or disposition) back to the issuer | 45.3M shares |
|---|---|
| Bona fide gift | 454K shares |
| Other acquisition or disposition | 2.37M shares |
| Open market or private sale | 92.7K shares |